Immunotherapy and radiotherapy for metastatic cancers

Andrew Bang¹, Jonathan D. Schoenfeld²

¹Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada; ²Department of Radiation Oncology, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, MA, USA

Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: A Bang; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Jonathan D. Schoenfeld, MD, MPH. Assistant Professor, Department of Radiation Oncology, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, 450 Brookline Ave, DA L2-57, Boston, MA, USA. Email: Jonathan_Schoenfeld@dfci.harvard.edu.

Abstract: Immune checkpoint inhibitors have emerged as a breakthrough therapy in the treatment in various metastatic cancers. In parallel, the role of radiotherapy in metastatic cancers has been expanding to include stereotactic ablative radiotherapy for oligometastases, in addition to the more conventional palliation of symptoms. Thus, many patients are appropriate candidates for both radiation and immunotherapy—highlighting the need for data to guide this treatment combination in patients with metastatic disease. Here, we review the literature to address questions regarding the safety of combined treatment (focusing on radionecrosis and pneumonitis), and the impact of dose, timing and site of radiotherapy. Finally, we highlight ongoing work investigating the potential local and systemic benefit to combining these therapies.

Keywords: Checkpoint inhibitors; immunotherapy; metastatic; PD-1 inhibitors; radiotherapy

Submitted Jun 19, 2018. Accepted for publication Jul 25, 2018. doi: 10.21037/apm.2018.07.10

Introduction

Immune checkpoint inhibitors (ICIs) have dramatically altered the landscape of treatment for metastatic solid tumors. By removing the “brakes” on the immune system, agents that target the inhibitory CTLA-4 and PD-1 receptors invigorate anti-tumor immune responses. Numerous landmark trials demonstrate the effectiveness of ICIs across tumor histologies, including malignant melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), urothelial carcinoma, head and neck squamous cell carcinoma (HNSCC), gastric adenocarcinoma, mismatch-repair-deficient solid tumors, Hodgkin’s lymphoma and Merkel cell carcinoma, where treatment with a CTLA-4, PD-1, or PD-L1 inhibitor are FDA-approved (1-9). Particularly notable among successful landmark phase 3 immunotherapy trials is a population of long-term responders along with a relatively larger population of non-responders who derive minimal, if any, benefit from therapy (10). This potential for long-term benefit, which has now extended beyond a decade in melanoma patients, has ignited intense interest in combination treatment strategies, with the goal of maximizing the number of these long-term responders (11). Early successes include the combination of PD-1 and CTLA-4 inhibition in melanoma and renal cell carcinoma (12,13), as well as PD-1 inhibition and chemotherapy in patients with metastatic non-small cell lung cancer (14).

Take home points:
(I) Palliative radiotherapy and more recently, immune checkpoint therapy occupy a prominent role in the treatment of metastatic disease. The combination of these treatments appears to be generally well tolerated, although practitioners need to be vigilant to identify and treat immune mediated toxicities. Potential impacts on radionecrosis in patients receiving stereotactic radiosurgery and immune checkpoint inhibitors must be balanced against favorable clinical outcomes now observed with the combination of the two treatments.

(II) Emerging data suggest that the addition of...
radiation to patients with limited progression on immunotherapy may be an effective treatment strategy to allow select patients to continue to benefit from immune checkpoint blockade.

(III) Preclinical studies and clinical data have suggested that the addition of radiotherapy to immune checkpoint blockade could improve systemic response rates—this strategy is being evaluated in prospective clinical trials.

Given that the majority of solid tumor patients will receive radiation therapy over the course of their illness (15), the combination of radiotherapy and immunotherapy for metastatic cancers is particularly appealing. In preclinical models, radiotherapy combined with ICI both enhances the local impact of radiation and the systemic effects of immunotherapy. The immunogenic effects of radiation include enhanced STING (stimulator of interferon genes) pathway activation, antigen presentation, T-cell activation and trafficking that may complement the immune effects of both CTLA-4 and PD-1 pathway inhibition (16). In particular, radiotherapy gives rise to increased uptake of exogenous DNA into the cytoplasm, upregulating interferon production through the cGAS-STING pathway, which in turn helps facilitate a mounted adaptive immune response (17). There is significant interest in understanding and harnessing rare abscopal responses that occur outside of the treatment field following targeted radiation that are likely immune mediated. However, when administered in combination with ICI, it becomes challenging to distinguish between the abscopal effect, enhanced activity of ICI, and delayed and atypical patterns of response that can be observed after both CTLA-4 and PD-1 monotherapy (18-22). Thus, prospective and ideally, randomized trials incorporating ICI and radiation are needed to demonstrate benefit.

Additionally, synergy between radiation and immunotherapy is a double-edged sword, potentially increasing the risk of either radiotherapy-mediated or immune-mediated toxicity. Inhibiting important immunologic checkpoints could increase immune cell-mediated normal tissue damage at the irradiated site. Conversely, by provoking normal tissue injury or acting through immunologic pathways, radiotherapy could worsen immune-related adverse events (ir-AEs) observed with ICIs.

In this review, we discuss the literature and present the current clinical data on the safety of combining ICIs with radiotherapy in patients with metastatic cancers, focusing on associations with the timing of radiation administration, as well as on two toxicities of particular concern in metastatic patients receiving either brain or lung directed radiation: radionecrosis of the brain and pneumonitis. Finally, we examine the potential benefit of radiation/immunotherapy combinations on both local and systemic responses, and look towards the future to explore how to maximize benefit.

**Toxicity**

**Overall rates of toxicity**

One of the potential advantages of immunotherapy as compared to cytotoxic chemotherapy is the side effect profile which is distinct and often better tolerated. Immunologic toxicities associated with ICI vary by class of agent and include fatigue, dermatitis, myalgias, thyroid dysfunction, colitis and pneumonitis (23). However, although these immunologic toxicities are low grade in many patients, they can be severe or even fatal. Prompt recognition and treatment is required to minimize the risk of serious toxicity (24). Thus, identifying any heightened risks associated with the combination of radiation and immunotherapy is paramount.

Only recently have the first prospective studies examining the combination of radiotherapy and immunotherapy in the setting of metastatic disease been reported (Table 1). In these reports, grade 3–5 toxicities have ranged from 14–34% in trials using CTLA-4 inhibitors and 5–10% in patients receiving PD-1 inhibitors, generally consistent with the side effect profile expected with immune checkpoint therapy alone. Furthermore, there were few serious side effects attributed to the radiation component of treatment (18,25-30). However, none of these aforementioned studies randomized patients between ICI alone and ICI with radiotherapy, limiting the conclusions that can be drawn. More recently however, Theelen et al. and McBride et al. presented preliminary data at ASCO 2018 from two phase II randomized trials exploring the use of PD-1 inhibition with or without hypofractionated radiotherapy in patients with metastatic NSCLC and metastatic HNSCC, respectively. Theelen et al. demonstrated a grade 3+ toxicity rate of 22% in the control arm vs. 17% in the experimental arm (31) while McBride et al. demonstrated grade 3+ toxicities of 15% and 11% in the control and experimental arms, respectively (32). Additionally, although the phase 3 randomized PACIFIC study included locally advanced stage 3 NSCLC patients and not patients with metastatic disease, it was reassuring that grade 3+ toxicities were relatively balanced following definitive chemoradiation between the ICI and control groups (33).

Thus, the combination of ICI and radiotherapy appears
<table>
<thead>
<tr>
<th>Study</th>
<th>Cancer histology</th>
<th>Immune checkpoint inhibitor</th>
<th>Site of treatment</th>
<th>SBRT/SRS</th>
<th>Dose/fractionation</th>
<th>Timing of radiation with ICI</th>
<th>Local response rate</th>
<th>Systemic response rate</th>
<th>Median survival</th>
<th>Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kwon et al. [2014]; phase III</td>
<td>Prostate</td>
<td>Anti-CTLA-4: ipilimumab</td>
<td>Bone</td>
<td>No</td>
<td>8 Gy in 1 fraction</td>
<td>Pre ≤2 days</td>
<td>–</td>
<td>–</td>
<td>OS: 11.2 months</td>
<td>All grade: 75%; PFS: 4.0 months; Grade 3+: 26% Grade 5: 1%</td>
</tr>
<tr>
<td>Tywan St. Victor et al. [2015]; phase I</td>
<td>Melanoma N=22</td>
<td>Anti-CTLA-4: ipilimumab</td>
<td>Lung, liver subcutaneous, lymph nodes</td>
<td>No</td>
<td>12 Gy in 2 fractions; 16 Gy in 2 fractions; 18 Gy in 3 fractions; 24 Gy in 3 fractions</td>
<td>Pre 3–5 days</td>
<td>CR: 5%; PR: 27%; SD: 41%</td>
<td>CR: 0%; PR: 18%; SD: 18%</td>
<td>OS: 10.7 months</td>
<td>–</td>
</tr>
<tr>
<td>Hiniker et al. [2016]; phase II</td>
<td>Melanoma N=22</td>
<td>Anti-CTLA-4: ipilimumab</td>
<td>Lung, liver, bones, lymph nodes, bowel, brain</td>
<td>Mixed</td>
<td>SBRT: 18 Gy/1 – 50 Gy/4; palliative: 20 Gy/5 – 45 Gy/15</td>
<td>Post ≤5 days</td>
<td>CR: 32%; PR: 41%; SD: 27%</td>
<td>CR: 14%; PR: 14%; SD: 23%</td>
<td>OS: 12.8 months</td>
<td>All grade: 68%</td>
</tr>
<tr>
<td>Tang et al. [2017]; phase I</td>
<td>Solid tumor N=35</td>
<td>Anti-CTLA-4: ipilimumab</td>
<td>Lung, liver</td>
<td>Yes</td>
<td>50 Gy in 4 fractions; 60 Gy in 10 fractions</td>
<td>Concurrent or post 7 days</td>
<td>CR: 6%; PR: 10%; SD: 29%</td>
<td>CR: 0%; PR: 0%; SD: 55%</td>
<td>OS: 10.2 months</td>
<td>Grade 5: 0%</td>
</tr>
<tr>
<td>Welsh et al. [2017]; phase II</td>
<td>Solid tumor N=100</td>
<td>Anti-CTLA-4: ipilimumab</td>
<td>Lung, liver</td>
<td>Yes</td>
<td>50 Gy in 4 fractions; 60 Gy in 10 fractions</td>
<td>Concurrent or post 7 days</td>
<td>–</td>
<td>–</td>
<td>OS: 12 months</td>
<td>Grade 3+: 27%</td>
</tr>
<tr>
<td>Williams et al. Melanoma [2017]; phase I</td>
<td>Brain Mixed</td>
<td>Anti-CTLA-4: ipilimumab</td>
<td>Brain</td>
<td>Mixed</td>
<td>15 Gy in 1 fraction; 18 Gy in 1 fraction; 24 Gy in 1 fraction; 30 Gy in 10 fractions</td>
<td>Concurrent</td>
<td>–</td>
<td>–</td>
<td>OS: 8 months</td>
<td>–</td>
</tr>
<tr>
<td>Luke et al. [2018]; phase II</td>
<td>Solid tumor N=79</td>
<td>Anti-PD-1: pembrolizumab</td>
<td>Lung, liver, bone, abdomen/pelvis</td>
<td>Yes</td>
<td>30 Gy in 3 fractions; 45 Gy in 3 fractions; 50 Gy in 5 fractions</td>
<td>Post ≤7 days</td>
<td>–</td>
<td>CR: 1%; PR: 12%; SD: 31%</td>
<td>OS: 9.6 months</td>
<td>Grade 3+: 10%</td>
</tr>
</tbody>
</table>

SBRT/SRS, stereotactic body radiotherapy/stereotactic radiosurgery; ICI, immune checkpoint inhibitor; Gy, Gray; OS, overall survival; PFS, progression free survival; CR, complete response; PR, partial response; SD, stable disease.
to be generally safe in most patients. It should be noted that grade 3–4 adverse events were more common in two trials conducted at a single institution in which ablative doses of radiotherapy (60 Gy delivered over 10 fractions, 50 Gy delivered over 4 fractions) were combined with the CTLA-4 inhibitor ipilimumab. Although these patients received ipilimumab at a dose of 3 mg/kg (approved for the treatment of metastatic melanoma patients), a grade 3–4 adverse event rate of 30% was more comparable to historical rates associated with ipilimumab dosed at 10 mg/kg (27). Reassuringly, these increased severe toxicity rates were not observed in other prospective trials combining radiation with ipilimumab, nor in the recently published prospective study by Luke et al., combining relatively high dose stereotactic body radiotherapy (SBRT) with the PD-1 inhibitor pembrolizumab where grade 3–4 toxicities were observed in 10% of patients (30).

Although prospective data is limited, especially in regards to combinations with PD-1 inhibitors and radiation dose/fractionation regimens most commonly used in the setting of palliative treatment, there has been an expanding number of retrospective studies evaluating outcomes (Table 2) (34-54). Reassuringly, in these studies, grade 3 or higher toxicities have ranged from 8–41% in patients treated with CTLA-4 inhibitors and 5–13% with PD-1 inhibitors, again consistent with the historical rates of adverse events with ICI alone. In a systematic review of studies combining SRS and ICIs, the authors found that although the literature was limited, concurrent therapy in the treatment of brain mets appeared to be safe overall (55). In our recently published series, we found that overall, rates of all grade (35%) and grade 3+ toxicities (8%) were consistent with historical controls (43). We did not note any correlation between the sites of radiotherapy in increasing the rate of an associated adverse event (Figure 1) (43). Interestingly, there was an association between any grade ir-AEs and biologically effective radiation dose (BED) (P=0.01) as shown in Figure 2 (43). However, there was no association between BED and severe toxicity, and statistical significance was lost when evaluating only patients who received radiotherapy and a PD-1 inhibitor as opposed to a CTLA-4 inhibitor (43), similar to the findings in Luke et al.

Questions regarding timing of therapy and development of toxicity

The relevance of timing, sequencing and interval between radiation and ICI is an increasingly common practical question for radiation and medical oncologists alike. It should be noted that in the prospective clinical trials published to date, radiotherapy was delivered concurrently or within 7 days of the administration of ICIs (18,25-32) with the exception of the PACIFIC trial, where patients were randomized between 1–42 days following chemoradiotherapy (33).

Several of the retrospective studies summarized in Table 2 investigated whether the sequencing (radiation before vs. after) or temporal proximity of radiation to ICI impacted overall rates of toxicity. With regards to the sequencing of therapies, both our group as well as Qin et al. did not identify a significant difference in the rates of ir-AEs depending on the sequencing of the two therapies (40,43). In contrast, there may be an association between the temporal proximity of the two treatments and overall toxicity rates. Kiess et al. evaluated patients with advanced melanoma treated with a CTLA-4 inhibitor and stereotactic radiosurgery (SRS), and demonstrated a higher rate of grade 3–4 toxicity when SRS was given “concurrently”, defined by the delivery of SRS within 1 month of the ICI (47% vs. 16%) (37). We identified a trend towards higher all grade ir-AEs when radiation was delivered within 2 weeks of the receipt of an ICI (39% vs. 23%, P=0.06), but there were no differences noted in the rate of grade 3–4 toxicities (43). It remains unproven whether radiation given in close sequence to ICI increases the rates of toxicity compared to radiation given concurrently. However, given the prolonged half-life and mechanism of action of these drugs, this seems unlikely. Ongoing and future prospective studies investigating the timing of radiotherapy in relation to ICI will help better establish whether there is any association between toxicity and either the sequencing and/or interval between treatments (56).

One of the most important limitations to identifying associations between combination radiation/ICI treatment and toxicity is that both immune and radiation-induced toxicities can manifest late months, or even years in the case of radiotherapy. Thus, long-term follow up of prospective clinical trials will be important to further investigate any potential increase in toxicity rates. In the meantime, vigilance is needed to identify toxicities with later onset. Multidisciplinary communication and collaboration is essential, especially in cases where patients have discontinued ICI treatment and may be receiving radiation monotherapy when they develop ir-AEs, or to help identify previous radiation treatment fields when toxicity develops after starting ICI. Particularly relevant to the latter are
<table>
<thead>
<tr>
<th>Study</th>
<th>Cancer histology</th>
<th>Immune checkpoint inhibitor</th>
<th>Site of treatment</th>
<th>SBRT/SRS</th>
<th>Dose/fractionation</th>
<th>Timing of radiation with ICI</th>
<th>Local response rate</th>
<th>Systemic response rate</th>
<th>Survival</th>
<th>Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barker et al.</td>
<td>Melanoma N=29</td>
<td>Anti-CTLA-4: ipilimumab</td>
<td>Extracranial</td>
<td>Mixed</td>
<td>25 Gy in 10 fractions; 24 Gy in 1 fraction; 28.5 Gy in 3 fractions; 30 Gy in 10 fractions; 30 Gy in 5 fractions; 30 Gy in 3 fractions</td>
<td>Concurrent</td>
<td>–</td>
<td>–</td>
<td>mOS: 9 months (induction)</td>
<td>Grade 3+: 41%</td>
</tr>
<tr>
<td>Ahmed et al.</td>
<td>Melanoma N=26</td>
<td>Anti-CTLA-4: ipilimumab</td>
<td>Brain</td>
<td>Yes</td>
<td>20–30 Gy in 5 fractions; 16–24 Gy in 1 fraction</td>
<td>Variable</td>
<td>1 y-LC: 85%</td>
<td>–</td>
<td>mOS: 11.8 months</td>
<td>All grade: 15% Grade 3+: 8%</td>
</tr>
<tr>
<td>Kiess et al.</td>
<td>Melanoma N=46</td>
<td>Anti-CTLA-4: ipilimumab</td>
<td>Brain</td>
<td>Yes</td>
<td>15–24 Gy in 1 fraction</td>
<td>Variable</td>
<td>1 y-LC: 87%</td>
<td>–</td>
<td>mOS: 12.4 months</td>
<td>Grade 3+: 20%</td>
</tr>
<tr>
<td>Colaco et al.</td>
<td>Melanoma, lung,</td>
<td>Anti-CTLA-4: anti-PD-1</td>
<td>Brain</td>
<td>Yes</td>
<td>15–24 Gy in 1 fraction</td>
<td>Variable</td>
<td>–</td>
<td>–</td>
<td>mOS: 9.3 months</td>
<td>Radionecrosis: 33%</td>
</tr>
<tr>
<td></td>
<td>RCC, breast, CRC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liniker et al.</td>
<td>Melanoma N=35</td>
<td>Anti-PD-1: nivolumab,</td>
<td>All</td>
<td>Mixed</td>
<td>8–30 Gy in 1–10 fractions</td>
<td>Variable</td>
<td>CR: 10%; PR: 43%; SD: 27%</td>
<td>CR: 22%; PR: 26%; SD: 31%</td>
<td>mOS: 6.4 months (C*) 8.6 months (S*); P=0.77</td>
<td>Grade 3+: 11%</td>
</tr>
<tr>
<td>Qin et al.</td>
<td>Melanoma N=44</td>
<td>Anti-CTLA-4: ipilimumab</td>
<td>Extracranial</td>
<td>Mixed</td>
<td>18–42 Gy in 1–16 fractions</td>
<td>Variable</td>
<td>–</td>
<td>–</td>
<td>mOS: 17.9 months</td>
<td>Grade 3+: 18% 15.9 months (B*); 17.9 months (A*); P=0.59</td>
</tr>
<tr>
<td></td>
<td></td>
<td>pembrolizumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6 m-PFS: 65%</td>
<td>Grade 3+: 7%</td>
</tr>
<tr>
<td>Anderson et al.</td>
<td>Melanoma N=21</td>
<td>Anti-PD-1: pembrolizumab</td>
<td>Brain</td>
<td>Mixed</td>
<td>30 Gy in 5 or 10 fractions; 18–21 Gy in 1 fraction</td>
<td>Concurrent</td>
<td>CR: 35%; PR: 35%; SD: 26%</td>
<td>–</td>
<td>–</td>
<td>Grade 3+: 5%</td>
</tr>
</tbody>
</table>

Table 2 (continued)
<table>
<thead>
<tr>
<th>Study</th>
<th>Cancer histology</th>
<th>Immune checkpoint inhibitor</th>
<th>Site of treatment</th>
<th>SBRT/SRS</th>
<th>Dose/fractionation</th>
<th>Timing of radiation with ICI</th>
<th>Local response rate</th>
<th>Systemic response rate</th>
<th>Survival</th>
<th>Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bang et al. [2017]</td>
<td>Melanoma, Lung,</td>
<td>Anti-CTLA-4: ipilimumab;</td>
<td>All</td>
<td>Mixed</td>
<td>8–66 Gy in 1–33 fractions</td>
<td>Variable</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>All grade: 35%</td>
</tr>
<tr>
<td></td>
<td>RCC N=133</td>
<td>anti-PD-1: pembrolizumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Grade 3+: 8%</td>
</tr>
<tr>
<td>Fang et al. [2017]</td>
<td>Melanoma N=137</td>
<td>Anti-CTLA-4: ipilimumab;</td>
<td>Brain</td>
<td>Mixed</td>
<td>12–24 Gy in 1 fraction</td>
<td>Variable</td>
<td>–</td>
<td>–</td>
<td>mOS: 16.9 months</td>
<td>Radionecrosis: 27%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>anti-PD-1: nivolumab,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Symptomatic RN: 15%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>pembrolizumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hwang et al. [2017]</td>
<td>Lung N=73</td>
<td>Anti-PD-1; Anti-PD-L1</td>
<td>Lung</td>
<td></td>
<td></td>
<td>mOS: 12.1 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kairadar-Person et al. [2017]</td>
<td>Melanoma N=29</td>
<td>Anti-CTLA-4: ipilimumab;</td>
<td>Brain</td>
<td>Yes</td>
<td>21–30 Gy in 3–5 fractions; 18–20 Gy in 1 fraction</td>
<td>Variable</td>
<td>1y-LC: 52%</td>
<td>–</td>
<td>mOS: 15 months</td>
<td>Radionecrosis: 28%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>anti-PD-1: nivolumab,</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Symptomatic RN: 21%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>pembrolizumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hemorrhage 24%</td>
</tr>
<tr>
<td>Patel et al. [2017]</td>
<td>Melanoma N=20</td>
<td>Anti-CTLA-4: ipilimumab</td>
<td>Brain</td>
<td>Yes</td>
<td>15–21 Gy in 1 fraction</td>
<td>Variable</td>
<td>1y-LC: 71%</td>
<td>–</td>
<td>1y-OS: 37%</td>
<td>Radionecrosis: 30%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Symptomatic RN: 15%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hemorrhage 15%</td>
</tr>
<tr>
<td>Pike et al. [2017]</td>
<td>Melanoma, lung,</td>
<td>Anti-PD-1: nivolumab,</td>
<td>All</td>
<td>Mixed</td>
<td>8–66 Gy in 1–33 fractions</td>
<td>Variable</td>
<td>–</td>
<td>–</td>
<td>mOS: 23.5 months</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>RCC N=137</td>
<td>pembrolizumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shaverdian et al. [2017]</td>
<td>NSCLC N=42</td>
<td>Anti-PD-1: pembrolizumab</td>
<td>Lung</td>
<td>Mixed</td>
<td>–</td>
<td>Pre</td>
<td>–</td>
<td>–</td>
<td>mOS: 10.7 months</td>
<td>All grade pulmonary: 63%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PFS: 4.4 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Grade 3+ pulmonary: 13%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hemorrhage: 18%</td>
</tr>
<tr>
<td>Study</td>
<td>Cancer histology</td>
<td>SBRT/SRS, stereotactic body radiotherapy/stereotactic radiosurgery</td>
<td>Immune checkpoint inhibitor</td>
<td>Site of treatment</td>
<td>SBRT/ SRS</td>
<td>Dose/fractionation</td>
<td>Timing of radiation with ICI</td>
<td>Local response rate</td>
<td>Systemic response rate</td>
<td>Survival</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------</td>
<td>-------------------------------------------------</td>
<td>-----------------------------</td>
<td>------------------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-----------------------------</td>
<td>-------------------</td>
<td>-----------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Gabani et al. [2018]</td>
<td>Melanoma N=288</td>
<td>Extracranial</td>
<td>Anti-CTLA-4; anti-PD-1; IL-2; tumor vaccines</td>
<td>Mixed</td>
<td>8–67.5 Gy; SBRT: 20–50 Gy in 1-5 fractions</td>
<td>Variable</td>
<td>–</td>
<td>–</td>
<td>mOS: 15.4 months</td>
<td>–</td>
</tr>
<tr>
<td>Hubbeling et al. [2018]</td>
<td>NSCLC N=50</td>
<td>Brain</td>
<td>Anti-PD-1; nivolumab, pembrolizumab; anti-PD-L1: atezolizumab</td>
<td>Mixed</td>
<td>20–37.5 Gy in 10–15 fractions; SRS: 10–22 Gy in 1 fraction</td>
<td>Variable</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>All grade (SRS): 57%</td>
</tr>
<tr>
<td>Martin et al. [2018]</td>
<td>Melanoma, lung, RCC N=115</td>
<td>Brain</td>
<td>Anti-CTLA-4: ipilimumab; anti-PD-1: nivolumab pembrolizumab</td>
<td>Yes</td>
<td>25–30 Gy in 5 fractions 18–20 Gy in 1 fraction</td>
<td>Variable</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Grade 3+ (SRS): 9%</td>
</tr>
</tbody>
</table>

SBRT/SRS, stereotactic body radiotherapy/stereotactic radiosurgery; ICI, immune checkpoint inhibitor; Gy, Gray; mOS, median overall survival; LC, local control; CR, complete response; PR, partial response; SD, stable disease; C*, concurrent; S*, sequential; B*, before; A*, after; PFS, progression free survival; RN, radionecrosis; WBRT, whole brain radiotherapy.
reports of recall ir-AEs that are localized to the radiation treatment field (57), which can only be recognized if the details of previous radiation treatment are known.

**Brain radionecrosis**

Although there is evidence that ICI monotherapy is efficacious in the brain (58,59), most patients with intracranial metastases are considered for radiotherapy, especially for histologies other than melanoma, where response rates to ICI are more limited. Thus, an increasing number of patients are treated with the combination of brain-directed radiotherapy and ICI. More specifically, the use of SRS for patients with limited numbers of brain metastases has continued to increase; thus, many of these patients will receive SRS in the setting of ICI. While it can be challenging to differentiate radionecrosis from progression or pseudoprogression, several retrospective studies have estimated that following SRS treatment, radiographic radionecrosis rates range from 16–33% (38,44,46,47,54), while symptomatic radionecrosis rates range from 12–21% (44,46,47,53,54). To help answer the question of whether the addition of ICIs increases the risk of radionecrosis, Martin et al. and Kaidar-Person et al. compared rates among patients who were treated with SRS and those who received both SRS and ICIs. Martin et al. studied 480 patients who received SRS in a mixed population (melanoma, NSCLC, RCC). They found that patients who received a CTLA-4 or PD-1 inhibitor had higher rates of symptomatic radionecrosis than those who received SRS alone (20% vs. 7%, HR 2.56, P=0.004) (53). Patients with metastatic melanoma appeared to be more susceptible to increased rates of symptomatic radionecrosis (HR 4.70, P=0.01) (53). Kaidar-Person et al. also demonstrated increased symptomatic radionecrosis rates of 21% compared to 0% in patients who did not receive an ICI (46). Comparing the impact of CTLA-4 inhibitors and PD-1 inhibitors, the study by Martin et al. demonstrated both classes of ICIs may numerically increase rates of radionecrosis, although the association with PD-1 inhibition...
was not statistically significant (HR 3.57, P=0.06) (53). Of note, an increasing number of studies demonstrate favorable survival in patients treated with the combination of SRS and brain metastases as compared to historical controls; this may impact the detection of radionecrosis in ways that are challenging to control for in retrospective studies.

Pneumonitis

In comparison to cytotoxic chemotherapy and CTLA-4 inhibitors, PD-1 inhibitors are associated with increased rates of pneumonitis. In a meta-analysis of 16 phase II/III studies, Wu et al. found the incidence of all grade pneumonitis was 2.9% and 1.5% for grade 3+ pneumonitis (60). Radiation-related pneumonitis is associated with a high dose of radiation to the lungs, and thus special attention is paid to the incidence of this toxicity when combining both treatments. When pneumonitis does develop in the setting of ICI in a patient previously treated with thoracic radiotherapy, it can be challenging to determine whether this is radiation or ICI related; this may have therapeutic implications if it prompts discontinuation of ICI therapy. Until better tools are available, evaluating the anatomical location of pneumonitis (radiation pneumonitis is generally localized to the radiation treatment field when detected in early stages, immune related pneumonitis is more diffuse) (61) and timing (radiation pneumonitis typically develops 2–9 months after radiotherapy (62) and immune related pneumonitis generally occurs between 0–19 months) (63) are generally the most helpful to guide attribution.

Reassuringly, there are several retrospective studies which have specifically evaluated rates of pneumonitis in ICI-treated patients who also received lung-directed radiation, finding no statistically significant difference in pneumonitis rates (43,45,49). In a secondary analysis of KEYNOTE-001, Shaverdian et al. found all grade pneumonitis rates of 8% vs. 1% (P=0.15) in patients who received thoracic-directed radiotherapy prior to ICI as compared to patients treated with ICIs alone (49). Hwang et al. retrospectively found all grade pneumonitis rates of 8% compared with 6% in patients previously treated with ICI combined with thoracic radiotherapy versus ICI alone (45). Interestingly, on multivariate analysis, they found that patients with an ir-AE had improved survival (HR 0.45, P=0.03) (45). Finally, the PACIFIC study, in which all patients received radiation to the lungs prescribed to at least 54 Gy administered 0–7 weeks before durvalumab, there was a modest numerical increase in any grade pneumonitis (34% vs. 25%) in patients that received durvalumab as compared to placebo that should, at least in part, be attributed to the rate of pneumonitis expected with durvalumab monotherapy (33). However, grade 3–4 pneumonitis rates were 3% in both arms (33).

Efficacy of combined treatment strategy

Local effects

Historically, chemotherapy and targeted agents have been used for radiosensitization to enhance the local effects of radiotherapy and to improve tumor control. While immunotherapies may not act as a radiosensitizer in a classical sense, preclinical and clinical evidence suggest that radiation is less effective when treating cancers in a state of immunosuppression (64). There are not yet any randomized trials in patients with metastatic disease comparing the local control rates of radiotherapy either administered alone or in combination with ICIs. In the setting of stage III NSCLC, the PACIFIC trial demonstrated an overall response rate of 28.4% compared to 16.0% when adding consolidative durvalumab and a disease control rate of 82.2% vs. 71.8% (33).

In the metastatic setting, several retrospective studies have compared local control rates in patients treated with combination SRS and ICI and SRS alone. Silk et al. found higher local response rates of 27% compared to 9% when SRS patients also received ipilimumab (35). However, disease control rates trended in the opposite direction (59% with ipilimumab, 68% without). In the studies performed by Kaidar-Person et al. and Patel et al., local control rates at 1-year were also numerically lower in patients treated with ipilimumab (52% vs. 86%, P=0.07 and 71% vs. 92%, P=0.40 in the two studies respectively) (46,47). However, local control following SRS is challenging to assess, especially in the setting of increased rates of radionecrosis/pseudoprogression that could potentially be observed following SRS and ICI. Pseudoprogression is not well accounted for using standard RECIST criteria, and thus alternative response criteria (irRC, iRECIST) are being utilized (21,22). More specifically for neuro-oncology, a response assessment has been developed by the RANO working group (65).

The local effects of radiotherapy could also be particularly valuable in metastatic patients who develop isolated sites of progression on ICI (66). The biologic explanation for this atypical pattern of resistance may be varied, but may, in some cases, be the result of localized loss of tumor antigens.
recognized by the immune system on ICI or other specific genetic changes mediating resistance (67–69). In cases such as these, focal radiation could ablate the area(s) of resistance, allowing for a sustained and more durable systemic response. Indeed, we found that among 59 patients who were treated with focal radiation for progression after starting a PD-1 inhibitor, 23 (39%) were able to continue to receive anti-PD-1 therapy for a median of 179 days (IQR 30–338, Figure 3) (48). In the future, better identification and biologic classification of patients with oligoprogression may further improve the utility of this combined treatment strategy.

**Using radiotherapy to improve systemic immunotherapy effects**

Given the favorable immunologic effects observed following radiation *in vitro*, one of the most provocative uses of radiotherapy being explored in the metastatic setting is to administer focal radiotherapy with the purpose of igniting a systemic immune response and overcoming either primary or acquired resistance to ICI. This work was encouraged by early case reports describing unusually favorable results obtained with the combination of radiation and ICI including a response outside of the radiation field (abscopal response) in a patient previously progressing on ipilimumab with biologic evidence of immune activation (18). Another case report demonstrated evidence of activity with ipilimumab combined with radiation in a heavily pretreated NSCLC patient (70)—a tumor type that does not generally respond to anti-CTLA-4 therapy. Although the PACIFIC study did not enroll metastatic NSCLC patients, this study also demonstrated an impressive PFS benefit with a hazard

---

**Figure 3** Timeline plot of patients with metastatic NSCLC and melanoma who received palliative radiation after progressing on anti-PD-1 therapy and were subsequently able to continue on anti-PD-1 therapy (red bars) for a median of 179 days (IQR 30–338 days). Blue, anti-PD-1 therapy delivered before RT; Red, anti-PD-1 therapy continued after RT; Grey, time off PD-1 inhibitor until death or last follow up; Blunt end, death; Pointed end, censored/ongoing follow up; Double Hash, survival beyond 1,000 days (1,491 days).
ratio of 0.52 (95% CI: 0.42–0.65, P<0.001) for the PD-L1 inhibitor durvalumab as compared to placebo in patients who received prior thoracic radiotherapy with concurrent chemotherapy (33). It remains unknown whether this more pronounced benefit for durvalumab, as compared to the benefit generally observed in the metastatic populations, was due to immune stimulating effects, eradication of gross disease prior to immunotherapy (10), or perhaps a combination of these two effects. Of note, patients who were randomized within 14 days of completing radiation demonstrated a more pronounced benefit to durvalumab as compared to placebo (HR for PFS 0.39, 95% CI: 0.26–0.58, as compared with HR 0.63, 95% CI: 0.49–0.80). A better understanding of the mechanisms underlying improved responses would help refine combined treatment strategies. Indeed, the existing radiation-immunotherapy studies mentioned above as well as other retrospective studies summarized in Table 2 are limited by significant heterogeneity regarding timing of radiation relative to ICI, sites and volume of disease to be radiated, and radiation dose/fractionation. Preclinical studies suggest these factors may impact results of combined radiation/ICI treatment significantly (71-74).

Conclusions

In summary, the combination of ICI and radiotherapy represents a promising treatment strategy for patients with metastatic cancers that is supported by preclinical evidence and early clinical data. Both prospective and an increasing amount of retrospective data suggest the combination of the two treatments is generally safe, although more study is needed to evaluate rare and late effects as well as to more accurately attribute toxicity to guide patient management. Additionally, potential increases in the rate of radionecrosis in patients receiving SRS and ICI must be balanced against the favorable clinical outcomes now observed with the combination of the two treatments (48), and is deserving of further study. In the meantime, the existing data is reassuring for the increasing number of patients who are candidates for ICI and palliative radiotherapy administered as standard of care treatment.

In addition, ongoing studies are evaluating the potential of a combined treatment strategy incorporating both radiotherapy and ICI to maximize benefit by addressing primary and acquired resistance to ICI, and by improving local control rates and palliative benefit achieved by radiation monotherapy. Existing clinical data suggests that radiotherapy can address localized progression in patients otherwise responding to immunotherapy; some of these patients can then continue to derive durable benefit from ICI. Unknown is whether the addition of radiotherapy to ICI will be able to reliably increase response rates as it has been demonstrated in preclinical models, and if so, the specifics of the patient, tumor and treatment parameters (type of ICI, timing, dose, fractionation and site of radiotherapy) required to maximize benefit.

Acknowledgements

None.

Footnote

Conflicts of Interest: JD Schoenfeld acknowledges research funding from BMS, Merck, and consulting fees from BMS, Debiopharm Group, AZ, Nanobiotix, and Tilos Therapeutics. Another author has no conflicts of interest to declare.

References


56. ClinicalTrials.gov [Internet]. Bethesda (MD): National


